Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label, Phase I Study to Assess the Safety and Clinical Activity of Multiple Doses of NKR-2, Administered Concurrently With the Neoadjuvant FOLFOX Treatment in Patients With Potentially Resectable Liver Metastases From Colorectal Cancer

Trial Profile

An Open-label, Phase I Study to Assess the Safety and Clinical Activity of Multiple Doses of NKR-2, Administered Concurrently With the Neoadjuvant FOLFOX Treatment in Patients With Potentially Resectable Liver Metastases From Colorectal Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 09 Nov 2018

At a glance

  • Drugs CYAD 01 (Primary)
  • Indications Adenocarcinoma; Colorectal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms SHRINK
  • Sponsors Celyad
  • Most Recent Events

    • 09 Nov 2018 According to a Celyad media release, results from this study will be presented at the the SITC 33rd Annual Meeting.
    • 29 Mar 2018 According to a Celyad media release, results from this study will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2018.
    • 17 Nov 2017 According to a Celyad media release, the dose escalation portion of the study will enroll up to 18 patients and the extension phase will enroll 21 additional patients.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top